six Slide seven Dave. summary to non-GAAP our and slide summarizes GAAP Thanks a results. of GAAP presentation measures, provides our of results
slide currency. a non-GAAP percent revenue declined of eight, X% margin revenue or XX basis Gross at increase you’ll X% to as measures on see looking points So the XX.X%. in constant
compared revenue. percent decreased of impact impact negative by Excluding QX, unfavorable XX.X% gross our basis on by product basis was gross percent approximately the margin on points the driven on XX XXXX, as mix international FX to revenue inventory of and price of same margin sold, and the a
products. the last expenses year's expenses grew investments quarter. containment X% Moving productivity cost administrative versus flat as selling Marketing, key offset were operating and measures and down P&L, in growth
income stage develop expenses Operating XXXX and increased increased growth, QX, selpercatinib full mirikizumab. to operating expenses compared percent access, a expense sales of for XX.X% including growth resulting for year. in as outpaced R&D revenue and an higher for the XX% income tirzepatide, and the quarter late of reflecting XX%, XX.X%
for margin expansion results offers. quarter's the our potential of new indicative portfolio medicines and This are growth of
of We expansion wave next while margin new exit strategy and invest with XX%. margin our full achieve We target the are on are XXXX XXXX our executing revenue medicines, significant momentum time. top-tier drive of in driving well positioned year to track same the to and growth operating at
$XXX expense million Other of this in by and QX, of million XXXX, was compared to driven equity. public $XX income on income investment gains quarter income
highlighted valuations Gains previously, item like Asia Lilly be ARM technologies strategic line we our market in were companies and China in this public fluctuate. in through generated primarily by focused QX companies our As as can volatile RNAi. in newer biotech investments Ventures investments
more we patients develop that While the investments. even pleased and relationships of medicines some to the we for gains, new these the with potential appreciate are accompany
income of net XX%, including discrete outstanding compared increase U.S. per year, bottom foreign from and from tax by the in tax due rate points primarily increased resolution decrease a shares an orders. tax was increased quarter benefits share with share last earnings benefits, repurchases. line a reduction to XX.X%, XXX basis Our the while XX%, the driven of in At net same
full the for measures the outlines non-GAAP nine Slide same year.
we impact QX overall our the and performance full Lartruvo. full for are experienced year While in are XXXX. of excited effect the we expiration the and with pleased year headed with Last momentum the Cialis our the in of we into patent withdrawal performance also XXXX, of the
newer EPS the In and in at growth our products top-line currency X% investing and spite we behind these of of pipeline. generated grew XX%, while headwinds constant
and and Oncology. the also are strategic acquisition shareholder Elanco established through value of good a of strong generating split-off Loxo We foundation, our
year, deliver XXXX last five highlighted goals are of in in period your our we this and we December well to sustained As positioned growth. financial continue
Moving between XX, will reconciliation EPS. slide non-GAAP you a to find and reported
and price, we Additional rate the slide provided On volume on slides XX, on details effect quality are XX of XX. revenue growth. and
strong by mentioned QX, As worldwide partially growth earlier, by XX% X% in grew revenue driven offset volume currency constant of during price.
a had negative modest on exchange revenue growth. Foreign impact
headwinds U.S. X% compared of For revenue we Verzenio, and XXXX, to the fourth worldwide X% growth Taltz, led revenue from expirations. patent the by delivered fourth grew straight Jardiance each Emgality. volume quarter of year Trulicity, was growth despite quarter
Lartruvo, and volume XX. over Cialis grew Excluding
drag and was discounts net growth was lower changes this higher quarter, segment, revenue disproportionate with rebates growth during expectations a headwind coverage U.S. volume XXXX full our partially consistent a reliance of for drag access price and and impact Emgality. price on having modest assistance as a to year improved offset on of primarily impacted commercial XXXX reduce price X% rebates, increases increased of on funding revenue Medicare, price unfavorable X% which gap by the patient net by estimates for moderate Pricing was list due in in as and in well for U.S. program, The growth.
effect to Moving driven by Taltz XX% Trulicity, revenue and and constant price. exchange by led current, foreign volume Europe, of partially by grew impressive Volume was growth, negative growth the Olumiant, Verzenio. XX% offset in
are are Europe of looking with new our We the XXXX. growth forward pleased across in products and to continued strong uptake
modest pricing the price contributors grow. went due in Cymbalta, in by government X% In XXXX. volume somewhat entirely the growth, and offset effect key a currency, constant decreases Japan driven by were Olumiant grew Trulicity mandated to that into Verzenio, to revenue headwind
the Revenue launches bottom in same constant the full performance growth the was of including key at are a number Trulicity, across our the excited led on world and China of increased XX% information by The the the recent is of rest slide. Olumiant. revenue products, Tyvyt, by year basis. we driven of so about Taltz currency same strong for China in XX% growth in
growth we've delivered As slide this drive new points worldwide seen throughout XXXX. continuing percentage volume XX, strong products growth. trajectory nearly to growth continue impressive medicines key our shown of These the quarter, on XX
Brands by drag that have points experienced provided Cialis. loss primarily a over of basis exclusively of driven XXX
QX market market. tadalafil revenue, the reminder, accelerating in with significantly generics entered impacting XXXX erosion U.S. generic in a as multisource further the Cialis entered XXXX, As September
event still beginning QX, on XXXX. negative While in is the this a to it’s impact impact growth meaningful of sunset, had
revenue of brands products. of $X.X generated Slide these XX the this over XX% total growth quarter contributions key revenue. billion making In our of highlights up
again and to the to continues strength growing patients execution. had in results our demonstrate therapeutic medicines newest impressive reach areas large our commercial and more of Our ability
XX% oral prescriptions to the injectable GLP-X faster that total than same the diabetes, injectable the new XXXX Trulicity increase and of continues class new XX% period. grew in the QX, entry despite therapy. grew clip patients add during market, of the In prescriptions U.S. an total versus hosting Within
in pricing expectations U.S. Trulicity digits declined the in-line for with and our mid-single the Net QX XXXX. for in for
SGLTX inhibitors prescription for to price of with growth last XXXX persist class the leader of in continues versus impacted As QX XX% therapy through accelerated for as drive grew their accounts prescription. Trulicity to and the QX full new over year’s the expect of market starts total XXXX. grew QX class don't a and by U.S. over call as we XX% factors trajectory that we in Jardiance quarter discussed number strong on nearly XX%
nearly have to two and for our future market well Taltz advantage competitive is growing growth In grew than XX% that sustained an leadership U.S. analogy share business and same XXXX. prescriptions important total have as during frame. for these time diabetes Taltz during in competitive Our Despite and gained us a rheumatology over three weekly continues XXXX market, points in increasingly diabetes within more versus classes positions growth. QX dermatology prescriptions doubled
even on reach XXXX continued pain, In of look in demonstrated and we more over for momentum U.S. and build brand patient. the leadership at share In to prescription market new XXXX strong to XX%. its Emgality
for there pleased presence additional room While is our with commercial expand as primary believe grow in we the uptake, care. we significant
strong see continue reimbursed prescriptions reflecting end the XX% to of progress of Emgality. access of at with We roughly QX, the
by over U.S increase six over is markets same the four timeframe. prescriptions showing during grew XX% encouraging the oncology, and XXXX Verzenio CDK total versus XX% growth total as QX and prescriptions Within
Additionally Cyramza our as synergies solid realize across continued we rapid portfolio. to the post growth
strong all have of and to the selpercatinib believe Rayvow, best to performance three growth potentially lives patients. our medicines in three look and in Lispro. drivers and XXXX, class class medicines forward improve potential in the key to We Ultra of new to first addition be Rapid new with In launching or
existing areas have addition, launching infrastructure margin further support expansion. will commercial to medicines therapeutic new In in where we
on margin, shows non-GAAP negative on change income revenue, and in XX, year-over-year and a expenses. focusing – Slide operating lines impact the gross income a operating moistest results, impact had statement, of positive on moderate our EPS, net foreign our select rates exchange
we investment an invested XXXX our capital after we provide tax On $XX business growth through billion capital over In combination development, of drive slide expenditures future a update R&D. in XX allocation. on to and
we shareholders dividend addition billion returned approximately and repurchases. $X In to share via
and the the increase the earlier, company. we our announced second Dave dividend mentioned confidence consecutive for XX% showing As for year, the outlook also
acquisitions create the recently develop focused grow new our utilizing We're Dermira. strong and next sources, to the flow or on of generates our cash We can medicines external bolt-on shareholder both internal enhance we where of announced highlighted active acquisition assessing future wave in-licensing business value remain by that’s in prospectus. through the and
slide our we've you'll of impact see our guidance that on planned a updated Dermira the recent reflect Turning of XX, the and non-GAAP acquisition to strong performance. guidance to XXXX business financial
and revenue by our business. strong increasing we to $XXX million we're range to in trends Specifically the see include reflect prescription underlying QBREXZA
sales guidance earnings of support our Updating to to an Dermira operating confirming SG&A the line all $X.XX force and non-GAAP our per items QBREXZA $X.XX, for margin share accounts maintaining to the and addition commercial and of target of expenses range other XX%. the
On a share expected reported for of have the $X.XX basis and range $X.XX earnings an will impact to XX. in Dermira acquisition be to the per now of XXXX $X. the is impact
strategy medicine margin execute while of to innovation over mid-term. drive our the We our new to based expansion continue portfolios leveraging commercial young
progress R&D. to highlight Dan Now, I’ll turn to the call our over on
